NCT03115138

Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: Centre Hospitalier Universitaire, Amiens · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Glioblastomas (GBM) are rare tumors of poor prognosis and their treatment is based on surgery followed by radiochemotherapy. Clinical and imaging evaluation is not always straightforward: the more or less complete surgery, the pseudo-progression after radiochemotherapy, the radionecrosis, the diagnosis of the relapse and the follow-up under anti-angiogenic can pose problems Clinicians and radiologists. Accessibility to a plasma tumor molecular marker would greatly facilitate the follow-up of these patients. It is now established for many cancers that circulating tumor DNA (cTNA) has the same molecular abnormalities as those identified in the primary tumor cells. Numerous studies have shown the prognostic value and diagnosis of the exploration of cDNA.

Conditions

• Glioblastoma
• Molecular Disease

Interventions

Type	Name	Description
OTHER	Correlation between molecular anomalies of the primary tumor and circulating tumor DNA	The presence of a specific abnormality initially identified on the primary tumor and which can be quantified in the cDNA during the management will allow a better follow-up of the patient.

Timeline

• Start date: 2016-03-09
• Primary completion: 2017-11-06
• Completion: 2017-11-06
• First posted: 2017-04-14
• Last updated: 2020-07-15

Locations

1 site across 1 country: France